Welcome to the tolvaptan training website intended for UK registered healthcare professionals (HCPs) only. Adverse event reporting can be found at the bottomThe Medicines and Healthcare Products Regulatory Agency (MHRA) requires Otsuka Pharmaceuticals (U.K.) Ltd. to ensure healthcare professionals who prescribe tolvaptan have access to additional Risk Minimisation Materials (aRMM) that provide important information regarding the appropriate use of the drug. Healthcare professionals can also register their details in the Enrolment form once they have read and understood the aRMM. This will enable Otsuka to send annual reminders to the prescribers about any material updates and will also issue an annual reminder to re-review the aRMM.Therefore, any HCP wishing to prescribe tolvaptan can complete the following:
  • Step 1: additional Risk Minimisation Materials
  • Step 2: Enrolment form
It is recommended that the materials on this site are used in conjunction with the full Summary of Product Characteristics.
The content of this website is managed by Otsuka Pharmaceuticals (U.K.) Ltd.
This website is funded by Otsuka Pharmaceuticals Europe Ltd.
Step 1| Training materialsStep 2| Enrolment

Step 1|Additional Risk Minimisation Materials

HCP Educational Guide

Discover more

Intended for prescribers and other healthcare professionals who are involved in the treatment of patients with autosomal dominant polycystic kidney disease with tolvaptan.

View Download

HCP Prescribing Checklist Electronic

Discover more

Intended to assist prescribers when assessing a patient’s suitability for tolvaptan at initiation and during on-going treatment.

View Download

Patient Alert Card

Discover more

Intended to be carried by patients with autosomal dominant polycystic kidney disease who are being treated with tolvaptan.
The patient alert card contains important safety information about tolvaptan for patients and carers.
It includes information on hepatic toxicity, severe dehydration and advice should such symptoms occur.

View Download

Patient Carer Education Brochure

Discover more

Intended to provide important safety information for patients with autosomal dominant polycystic kidney disease who are being treated with tolvaptan.

View Download
Printed copies of these aRMM are available by contacting .For further information please contact Otsuka Medical Information at or call +44 (0) 203 747 5300

Step 2|Enrolment

Thank you for reviewing the additional Risk Minimisation Materials (aRMM) for tolvaptan. If you wish to be informed about updates to these materials, please complete the enrolment form. Complete enrolment form